Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Harvard Medical School, and Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts.
Mol Cancer Ther (2024) 23 (10): 1365.
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Division of Hematology/Oncology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York. Department of Systems Biology, ...
The University of Texas MD Anderson Cancer Center, Houston, TX, United States ...
Major Finding: Coagulation factor X (FX) promotes proliferation and androgen independence in prostate cancer. Concept: Immunosuppressive neutrophils secrete FX, which binds PAR2 on PCa cells and ...
NVL-655, a fourth generation ALK tyrosine kinase inhibitor, was effective and well tolerated in the ALKOVE-1 trial in patients with ALK-positive non–small cell lung cancer that had previously been ...
University of Arkansas for Medical Sciences, Little Rock, AR, United States ...
Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...
Copyright held by the owner/author(s).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback